{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:55:31Z","timestamp":1776329731638,"version":"3.50.1"},"reference-count":24,"publisher":"Baskent University","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.6002\/ect.2022.0154","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T04:19:36Z","timestamp":1662005976000},"page":"789-791","source":"Crossref","is-referenced-by-count":1,"title":["Endovesical Bacillus Calmette-Gu\u00e9rin for Nonmuscle Invasive Bladder Cancer in Kidney Transplant Recipients: Is It Safe and Efficacious?"],"prefix":"10.6002","volume":"20","author":[{"given":"Thomas","family":"Prudhomme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iulia","family":"Andras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Boissier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Campi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vital","family":"Hevia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Territo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"European Association of Urology Young Academic Urologist","family":"Kidney Transplant Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4021","reference":[{"key":"ref0","unstructured":"References"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"1. Babjuk M, Burger M, Capoun O, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75-94. doi:10.1016\/j.eururo.2021.08.010","DOI":"10.1016\/j.eururo.2021.08.010"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"2. Hickman LA, Sawinski D, Guzzo T, Locke JE. Urologic malignancies in kidney transplantation. Am J Transplant. 2018;18(1):13-22. doi:10.1111\/ajt.14533","DOI":"10.1111\/ajt.14533"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"3. Boissier R, Thuret R, Prudhomme T, et al. [Urothelial carcinoma in kidney transplant recipients and candidates: the French guidelines from CTAFU]. Prog Urol. 2021;31(1):31-38. doi:10.1016\/j.purol.2020.04.028","DOI":"10.1016\/j.purol.2020.04.028"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"4. Lenis AT, Lec PM, Chamie K. Bladder cancer: a review. JAMA. 2020;324(19):1980-1991. doi:10.1001\/jama.2020.17598","DOI":"10.1001\/jama.2020.17598"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"5. Huang GL, Luo HL, Chen YT, Cheng YT. Oncologic outcomes of post-kidney transplantation superficial urothelial carcinoma. Transplant Proc. 2018;50(4):998-1000. doi:10.1016\/j.transproceed.2018.01.031","DOI":"10.1016\/j.transproceed.2018.01.031"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"6. Jue JS, Alameddine M, Gonzalez J, Ciancio G. Risk factors, management, and survival of bladder cancer after kidney transplantation. Actas Urol Esp (Engl Ed). 2021;45(6):427-438. doi:10.1016\/j.acuroe.2020.09.009","DOI":"10.1016\/j.acuroe.2020.09.009"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"7. Rodriguez Faba O, Palou J, Vila Reyes H, et al. Treatment options and predictive factors for recurrence and cancer-specific mortality in bladder cancer after renal transplantation: A multi-institutional analysis. Actas Urol Esp. 2017;41(10):639-645. doi:10.1016\/j.acuro.2017.05.007","DOI":"10.1016\/j.acuro.2017.05.007"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"8. Pradere B, Schuettfort V, Mori K, Quhal F, Aydh A, Sari Motlagh R. Management of de-novo urothelial carcinoma in transplanted patients. Curr Opin Urol. 2020;30(3):467-474. doi:10.1097\/MOU.0000000000000749","DOI":"10.1097\/MOU.0000000000000749"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"9. Master VA, Meng MV, Grossfeld GD, Koppie TM, Hirose R, Carroll PR. Treatment and outcome of invasive bladder cancer in patients after renal transplantation. J Urol. 2004;171(3):1085-1088. doi:10.1097\/01.ju.0000110612.42382.0a","DOI":"10.1097\/01.ju.0000110612.42382.0a"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"10. Hanna L, Ubee SS, Boddy J, Cooke PW. Efficacy and complications of intravesical BCG in immunocompromised patients. BJU Int. 2014;113(5):691-693. doi:10.1111\/bju.12562","DOI":"10.1111\/bju.12562"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"11. Roumeguere T, Broeders N, Jayaswal A, et al. Bacillus Calmette-Guerin therapy in non-muscle-invasive bladder carcinoma after renal transplantation for end-stage aristolochic acid nephropathy. Transpl Int. 2015;28(2):199-205. doi:10.1111\/tri.12484","DOI":"10.1111\/tri.12484"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"12. Gaughan EM, Dezube BJ, Bower M, et al. HIV-associated bladder cancer: a case series evaluating difficulties in diagnosis and management. BMC Urol. 2009;9:10. doi:10.1186\/1471-2490-9-10","DOI":"10.1186\/1471-2490-9-10"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"13. Herr HW, Dalbagni G. Intravesical bacille Calmette-Guerin (BCG) in immunologically compromised patients with bladder cancer. BJU Int. 2013;111(6):984-987. doi:10.1111\/j.1464-410X.2012.11778.x","DOI":"10.1111\/j.1464-410X.2012.11778.x"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"14. Ardelt PU, Rieken M, Ebbing J, et al. Urothelial cancer in renal transplant recipients: incidence, risk factors, and oncological outcome. Urology. 2016;88:104-110. doi:10.1016\/j.urology.2015.10.031","DOI":"10.1016\/j.urology.2015.10.031"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"15. Prabharasuth D, Moses KA, Bernstein M, Dalbagni G, Herr HW. Management of bladder cancer after renal transplantation. Urology. 2013;81(4):813-819. doi:10.1016\/j.urology.2012.11.035","DOI":"10.1016\/j.urology.2012.11.035"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"16. Miao Y, Everly JJ, Gross TG, et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation. 2009;87(9):1347-1359. doi:10.1097\/TP.0b013e3181a238f6","DOI":"10.1097\/TP.0b013e3181a238f6"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"17. Kamal MM, Soliman SM, Shokeir AA, Abol-Enein H, Ghoneim MA. Bladder carcinoma among live-donor renal transplant recipients: a single-centre experience and a review of the literature. BJU Int. 2008;101(1):30-35. doi:10.1111\/j.1464-410X.2007.07210.x","DOI":"10.1111\/j.1464-410X.2007.07210.x"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"18. Caravaca-Fontan F, Cano Megias M, Sanchez-Conde M, Elias Trivino S, Fernandez-Rodriguez A, Liano F. Subacute interstitial pneumonitis due to Mycobacterium bovis after intravesical bacillus Calmette-Guerin instillation in a renal transplant patient. Nefrologia. 2016;36(6):711-713. doi:10.1016\/j.nefro.2016.06.001","DOI":"10.1016\/j.nefro.2016.06.001"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"19. Ziegler J, Ho J, Gibson IW, et al. Disseminated Mycobacterium bovis infection post-kidney transplant following remote intravesical BCG therapy for bladder cancer. Transpl Infect Dis. 2018;20(5):e12931. doi:10.1111\/tid.12931","DOI":"10.1111\/tid.12931"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"20. Aznar Martinez L, Lopez Cubillana P, Lopez Abad A, Vidal Crespo N, Gomez Gomez GA. Bacillus Calmette-Guerin in immunosuppressed patient with high-grade nonmuscle invasive bladder carcinoma. Urol Int. 2019;103(2):242-244. doi:10.1159\/000501108","DOI":"10.1159\/000501108"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"21. Palou J, Angerri O, Segarra J, et al. Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation. 2003;76(10):1514-1516. doi:10.1097\/01.TP.0000090748.32764.0F","DOI":"10.1097\/01.TP.0000090748.32764.0F"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"22. Al Khalifa M, Elfving P, Mansson W, et al. The effect of isoniazid on BCG-induced toxicity in patients with superficial bladder cancer. Eur Urol. 2000;37 Suppl 1:26-30. doi:10.1159\/000052379","DOI":"10.1159\/000052379"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"23. van der Meijden AP, Brausi M, Zambon V, et al. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol. 2001;166(2):476-481. doi:10.1097\/00005392-200108000-00016","DOI":"10.1097\/00005392-200108000-00016"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T04:43:30Z","timestamp":1662007410000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ectrx.org\/detail\/archive\/2022\/20\/8\/0\/789\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2022.0154","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}